Clinical Feed

CLINICAL TRAJECTORY AND GENETIC LANDSCAPE OF NEONATAL-ONSET HYPERTROPHIC CARDIOMYOPATHY: INSIGHTS FROM A 30-YEAR MULTICENTER COHORT STUDY

Background: Neonatal-onset hypertrophic cardiomyopathy (HCM) is a rare condition with limited data regarding clinical presentation, genetic background, and long-term outcomes. We

GIST

Background: Neonatal-onset hypertrophic cardiomyopathy (HCM) is a rare condition with limited data regarding clinical presentation, genetic background, and long-term outcomes. We aimed to characterize the phenotype and prognosis of HCM presenting in neonates. Methods: This is a multicenter retrospective study including patients diagnosed with HCM before 1 year of age. Neonatal-onset HCM was defined as presentation {less than or equal to}28 days of life. Clinical, genetic, instrumental data, treatment, and outcomes were collected. Primary outcome included overall and cardiac survival, major arrhythmic events (MAEs), implantable cardioverter-defibrillator (ICD) implantation, and cardiac surgery. Results: Among 321 pediatric HCM, 21% were diagnosed during infancy and 75% were neonates. Median age at diagnosis was 1 day (IQR 0-6), 82% presented within the first week of life. Prenatal suspicion was in 25%. At presentation, 41% were symptomatic. RASopathies represented the most common etiology (41%), followed by gene-elusive (31%), mitochondrial/inborn errors of metabolism (18%), and sarcomeric (8%). Left ventricular outflow tract obstruction was frequent in sarcomeric and RASopathy.

Clinical Editorial

medRxiv (Clinical Preprints) published a clinical update in Research Highlights on 09 Jul 2026. The item focuses on CLINICAL TRAJECTORY AND GENETIC LANDSCAPE OF NEONATAL-ONSET HYPERTROPHIC CARDIOMYOPATHY: INSIGHTS FROM A 30-YEAR MULTICENTER COHORT STUDY. Review the original article for the full source wording and details.

Original source: https://www.medrxiv.org/content/10.64898/2026.07.06.26357420v1?rss=1